Tidal Investments LLC Acquires 275 Shares of Edwards Lifesciences Co. (NYSE:EW)

Tidal Investments LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,532 shares of the medical research company’s stock after purchasing an additional 275 shares during the period. Tidal Investments LLC’s holdings in Edwards Lifesciences were worth $2,609,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Peoples Bank KS bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $40,000. Finally, JFS Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $78.65.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,323,150 over the last 90 days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $73.32 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $69.42 and a 200-day moving average price of $73.90. The company has a market cap of $43.24 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 earnings per share. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.